stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Debt to equity
Immunome, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 0.5× (fiscal 2018) — the current reading is the lowest in ten years. That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | (93.00%) |
| FY2019 | 0.2× | (66.08%) |
| FY2018 | 0.5× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 25 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| BHVN Biohaven Ltd. compare | −2.7× |
| PVLA Palvella Therapeutics, Inc. compare | 0.0× |
| ADMA ADMA Biologics Inc compare | 0.0× |
| VCEL Vericel Corporation compare | 0.0× |
| IMNM Immunome, Inc. | 0.0× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
| CLDX Celldex Therapeutics, Inc. compare | 0.0× |
| AUPH Aurinia Pharmaceuticals Inc compare | 0.1× |
| VERA Vera Therapeutics, Inc. compare | 0.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement